From blood banking to advanced therapeutics: reframing transfusion medicine in the era of cell and gene therapy in China
Journal of Blood and Biotherapy · 27.05.2026 · 1 (1) · 23
DOI: 10.46701/jbbt260501 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Blood and Biotherapy, online erschienen am 27.05.2026. Verfasst von Yiming Ma und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cell and gene therapy (CGT) is rapidly reshaping the therapeutic landscape in China, where approved commercial products, registered clinical trials, investigator-initiated studies (IITs), and hospital-based translational platforms are developing in parallel. This pattern is especially pronounced in cellular therapeutics, including immune effector cell therapies, stem cell-based products, and selected cell-derived therapeutics. As living and highly individualized therapeutic products, these interventions require not only robust manufacturing processes but also safe and coordinated implementation within hospitals. A critical challenge lies in the hospital-based interval between manufacturing release and bedside administration, encompassing product receipt, chain of identity control, chain of custody maintenance, storage oversight, clinical release, and post-infusion surveillance. In this context, transfusion medicine should be reconsidered beyond its conventional function in blood banking. Transfusion medicine, as a hospital-based discipline with well-established expertise in apheresis, product identification, cold-chain management, traceability, and transfusion safety, possesses a competency profile that aligns closely with the unmet governance requirements of cellular therapy programs. This review examines the Chinese institutional context and contends that transfusion medicine can function as a coordinating governance interface between manufacturing and clinical application. Reframing transfusion medicine in this way may help strengthen hospital-based therapeutic stewardship, improve implementation safety, and support the sustainable development of advanced cellular therapies in China.
Zitieren
APA
Ma, Y., Li, X., & Jia, Y. (2026). From blood banking to advanced therapeutics: reframing transfusion medicine in the era of cell and gene therapy in China. Journal of Blood and Biotherapy, 1(1), 23. https://doi.org/10.46701/jbbt260501
Vancouver
Ma Y, Li X, Jia Y. From blood banking to advanced therapeutics: reframing transfusion medicine in the era of cell and gene therapy in China. Journal of Blood and Biotherapy. 2026;1(1):23. doi:10.46701/jbbt260501
BibTeX
@article{Ma2026,
author = {Ma, Yiming and Li, Xiaofei and Jia, Yu},
title = {From blood banking to advanced therapeutics: reframing transfusion medicine in the era of cell and gene therapy in China},
journal = {Journal of Blood and Biotherapy},
year = {2026},
volume = {1},
number = {1},
pages = {23},
doi = {10.46701/jbbt260501}
}
EUVIMED